Study of XL647 Administered Orally Daily to Patients With Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given orally daily to adults with advanced solid tumors.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subject has histologically confirmed malignancy that is metastatic or unresectable
Subject has disease that is assessable by tumor marker, physical, or radiologic means
Subject is at least 18 years old
Subject has an ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
Subject has a life expectancy ≥ 3 months
Subject has normal organ and marrow function
Subject gives written informed consent
Subject must use an accepted method of contraception during the study
Female subjects of childbearing potential must have a negative pregnancy test
Subject has received anticancer treatment within 30 days of first dose of XL647
Subject has received another investigational agent within 30 days of first dose of XL647
Subject has known brain metastases
Subject has corrected QT interval (QTc) of > 0.45 seconds
Subject is currently receiving anticoagulation therapy with warfarin